Findings from these trails led the leading cardiac (and diabetes) societies to recommend the use of SGLT2-inhibitors in patients with coronary artery disease with T2DM to reduce the risk of future CV events [29, 30]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.